金奥博(002917) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥244,975,986.71, representing a 16.58% increase compared to ¥210,137,200.63 in the same period last year[5] - Net profit attributable to shareholders reached ¥5,245,788.22, a significant increase of 3,276.20% from a loss of ¥165,159.06 in the previous year[5] - Basic and diluted earnings per share were both ¥0.0151, a substantial increase of 3,120.00% from a loss of ¥0.0005 per share in the same quarter last year[5] - Net profit for Q1 2023 was CNY 1,362,532.27, a significant recovery from a net loss of CNY 9,455,212.03 in Q1 2022[24] - The total comprehensive income attributable to the parent company was CNY 5,065,384.99, compared to a loss of CNY 250,230.52 in the previous period[25] Cash Flow - The net cash flow from operating activities improved to ¥4,796,949.78, marking a 114.04% increase from a negative cash flow of ¥34,171,017.84 in the prior year[5] - The net cash flow from investment activities increased by 64.91%, amounting to an increase of ¥38,743.06 million compared to the same period last year[11] - The net cash flow from investment activities was negative at CNY -209,448,658.63, compared to CNY -596,879,297.23 in the previous period[26] - Cash inflow from investment activities totaled CNY 216,147,112.32, down from CNY 885,240,709.53 in the previous period[26] - Operating cash inflows totaled CNY 245,083,009.39, compared to CNY 133,161,671.96 in the previous period, indicating a 84.3% increase[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,062,481,873.15, a slight increase of 0.06% from ¥3,060,677,777.88 at the end of the previous year[5] - The company's total liabilities increased to CNY 1,382,628,993.97, compared to CNY 1,367,043,157.85 in the previous quarter[21] - The equity attributable to shareholders of the parent company was CNY 1,442,513,418.21, down from CNY 1,453,138,728.52 in the previous quarter[21] Research and Development - The company reported a 31.15% increase in R&D expenses, totaling an increase of ¥394.67 million compared to the previous year[9] - Research and development expenses increased to CNY 16,618,220.54, representing a rise of 31.5% from CNY 12,671,533.23 in Q1 2022[22] Share Repurchase - As of March 31, 2023, the company has repurchased a total of 1,890,700 shares, accounting for 0.54% of the total share capital, with a total transaction amount of RMB 20,221,842.00[17] - The company plans to repurchase shares with a total amount not less than RMB 25 million and not exceeding RMB 50 million, with a price cap adjusted to RMB 13.94 per share[16] - The company has a plan for share repurchase to implement an employee stock ownership plan[16] Government Subsidies - The company received government subsidies amounting to ¥2,410,827.82, which is a 134.99% increase compared to the previous year[6] Inventory and Receivables - Accounts receivable increased to RMB 495,288,034.51 from RMB 437,334,159.07, reflecting a growth of approximately 13%[18] - The company’s inventory increased to RMB 257,521,957.73 from RMB 239,867,826.34, indicating a growth of about 7%[18] - The company’s other receivables rose to RMB 36,689,845.48 from RMB 33,681,072.11, marking an increase of approximately 9%[18] Operating Costs - Total operating costs for Q1 2023 were CNY 242,440,159.47, up from CNY 223,486,613.67 in the same period last year, reflecting a growth of 8.5%[22] Audit Status - The company did not conduct an audit for the first quarter report[27]